| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 157 | 2025 | 591 | 32.480 |
Why?
|
| Asthma | 131 | 2025 | 744 | 25.170 |
Why?
|
| Bronchodilator Agents | 70 | 2024 | 153 | 13.620 |
Why?
|
| Anti-Asthmatic Agents | 52 | 2024 | 108 | 13.350 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 25 | 2024 | 62 | 4.750 |
Why?
|
| Adrenal Cortex Hormones | 34 | 2024 | 317 | 4.700 |
Why?
|
| Forced Expiratory Volume | 52 | 2025 | 169 | 4.430 |
Why?
|
| Quality of Life | 43 | 2024 | 1923 | 4.380 |
Why?
|
| Eosinophils | 16 | 2024 | 121 | 3.890 |
Why?
|
| Lung | 30 | 2025 | 1463 | 3.710 |
Why?
|
| Administration, Inhalation | 46 | 2024 | 178 | 3.660 |
Why?
|
| Adrenergic beta-Agonists | 20 | 2020 | 93 | 3.370 |
Why?
|
| Omalizumab | 16 | 2024 | 32 | 3.230 |
Why?
|
| Exercise Tolerance | 8 | 2024 | 75 | 3.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 21 | 2025 | 489 | 2.910 |
Why?
|
| Anxiety | 13 | 2024 | 957 | 2.850 |
Why?
|
| Formoterol Fumarate | 18 | 2023 | 31 | 2.740 |
Why?
|
| Albuterol | 19 | 2018 | 52 | 2.590 |
Why?
|
| Dyspnea | 15 | 2024 | 147 | 2.500 |
Why?
|
| Humans | 289 | 2025 | 123046 | 2.500 |
Why?
|
| Depression | 15 | 2022 | 1218 | 2.420 |
Why?
|
| Double-Blind Method | 43 | 2025 | 1583 | 2.420 |
Why?
|
| Muscarinic Antagonists | 12 | 2024 | 38 | 2.400 |
Why?
|
| Anti-Inflammatory Agents | 11 | 2023 | 280 | 2.380 |
Why?
|
| Biological Products | 13 | 2023 | 113 | 2.350 |
Why?
|
| Chlorobenzenes | 10 | 2024 | 10 | 2.280 |
Why?
|
| Drug Therapy, Combination | 27 | 2024 | 1138 | 2.250 |
Why?
|
| Benzyl Alcohols | 9 | 2024 | 14 | 2.220 |
Why?
|
| Respiratory Function Tests | 21 | 2024 | 195 | 2.190 |
Why?
|
| Severity of Illness Index | 43 | 2024 | 2845 | 2.060 |
Why?
|
| Th2 Cells | 7 | 2021 | 187 | 1.870 |
Why?
|
| Nebulizers and Vaporizers | 24 | 2023 | 57 | 1.850 |
Why?
|
| Treatment Outcome | 62 | 2025 | 12109 | 1.840 |
Why?
|
| Pneumonia | 6 | 2023 | 325 | 1.830 |
Why?
|
| Androstadienes | 12 | 2024 | 49 | 1.800 |
Why?
|
| Aged | 83 | 2025 | 19083 | 1.800 |
Why?
|
| Ethanolamines | 12 | 2014 | 30 | 1.750 |
Why?
|
| Status Asthmaticus | 3 | 2023 | 20 | 1.740 |
Why?
|
| Glycopyrrolate | 5 | 2024 | 9 | 1.740 |
Why?
|
| Disease Progression | 27 | 2024 | 2028 | 1.620 |
Why?
|
| Scopolamine Derivatives | 5 | 2013 | 11 | 1.600 |
Why?
|
| Biomarkers | 26 | 2023 | 2943 | 1.560 |
Why?
|
| Middle Aged | 100 | 2025 | 25972 | 1.520 |
Why?
|
| Comorbidity | 26 | 2024 | 1496 | 1.440 |
Why?
|
| Quinuclidines | 6 | 2024 | 8 | 1.420 |
Why?
|
| Antibodies, Anti-Idiotypic | 6 | 2018 | 43 | 1.420 |
Why?
|
| Immunoglobulin E | 14 | 2025 | 161 | 1.380 |
Why?
|
| Interleukin-5 | 4 | 2019 | 44 | 1.360 |
Why?
|
| Glucocorticoids | 9 | 2021 | 377 | 1.330 |
Why?
|
| Male | 118 | 2025 | 60089 | 1.320 |
Why?
|
| Drug Combinations | 16 | 2024 | 269 | 1.320 |
Why?
|
| Tiotropium Bromide | 9 | 2024 | 14 | 1.290 |
Why?
|
| Vital Capacity | 14 | 2025 | 76 | 1.240 |
Why?
|
| Eosinophilia | 3 | 2023 | 101 | 1.230 |
Why?
|
| Female | 116 | 2025 | 65482 | 1.220 |
Why?
|
| Smoking | 18 | 2024 | 1030 | 1.220 |
Why?
|
| Nitric Oxide | 12 | 2024 | 439 | 1.210 |
Why?
|
| Primary Health Care | 5 | 2020 | 752 | 1.140 |
Why?
|
| Airway Obstruction | 5 | 2024 | 164 | 1.120 |
Why?
|
| Cell Adhesion Molecules | 6 | 2019 | 224 | 1.120 |
Why?
|
| Antibodies, Monoclonal | 8 | 2024 | 1008 | 1.120 |
Why?
|
| Phosphodiesterase Inhibitors | 5 | 2019 | 52 | 1.120 |
Why?
|
| Surveys and Questionnaires | 18 | 2024 | 3661 | 1.090 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 1862 | 1.060 |
Why?
|
| Pulmonary Emphysema | 4 | 2024 | 94 | 1.050 |
Why?
|
| Cost of Illness | 4 | 2019 | 242 | 1.040 |
Why?
|
| Influenza, Human | 5 | 2023 | 648 | 1.010 |
Why?
|
| Spirometry | 18 | 2024 | 74 | 1.010 |
Why?
|
| Adult | 67 | 2025 | 28972 | 0.970 |
Why?
|
| Metered Dose Inhalers | 7 | 2020 | 12 | 0.940 |
Why?
|
| Disease Management | 8 | 2024 | 514 | 0.910 |
Why?
|
| Patient-Centered Care | 4 | 2020 | 224 | 0.890 |
Why?
|
| Exercise | 2 | 2020 | 812 | 0.890 |
Why?
|
| Bronchitis, Chronic | 2 | 2021 | 18 | 0.870 |
Why?
|
| Phenotype | 18 | 2024 | 4226 | 0.870 |
Why?
|
| Molecular Targeted Therapy | 5 | 2020 | 353 | 0.860 |
Why?
|
| Cholinergic Antagonists | 4 | 2015 | 51 | 0.840 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 4 | 2019 | 8 | 0.830 |
Why?
|
| Leukotriene Antagonists | 3 | 2023 | 17 | 0.790 |
Why?
|
| Propofol | 1 | 2022 | 44 | 0.780 |
Why?
|
| Symptom Flare Up | 2 | 2020 | 24 | 0.750 |
Why?
|
| Hospitalists | 1 | 2021 | 45 | 0.740 |
Why?
|
| Anti-Allergic Agents | 4 | 2020 | 26 | 0.730 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 79 | 0.720 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2020 | 825 | 0.720 |
Why?
|
| Exercise Therapy | 3 | 2020 | 149 | 0.710 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 2393 | 0.700 |
Why?
|
| Prevalence | 14 | 2023 | 2395 | 0.690 |
Why?
|
| Hypersensitivity | 4 | 2023 | 182 | 0.670 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2019 | 2 | 0.660 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2019 | 8 | 0.650 |
Why?
|
| United States | 30 | 2024 | 10649 | 0.650 |
Why?
|
| Prostaglandin Antagonists | 1 | 2019 | 2 | 0.640 |
Why?
|
| Nadolol | 2 | 2010 | 28 | 0.640 |
Why?
|
| Receptors, Prostaglandin | 1 | 2019 | 22 | 0.640 |
Why?
|
| Triglycerides | 1 | 2021 | 561 | 0.610 |
Why?
|
| Receptors, Immunologic | 1 | 2019 | 109 | 0.610 |
Why?
|
| Hospitalization | 13 | 2022 | 1728 | 0.610 |
Why?
|
| Ketamine | 1 | 2022 | 214 | 0.600 |
Why?
|
| Glucose | 2 | 2021 | 875 | 0.600 |
Why?
|
| Health Status Disparities | 1 | 2020 | 220 | 0.600 |
Why?
|
| Aging | 5 | 2023 | 1176 | 0.590 |
Why?
|
| Breathing Exercises | 1 | 2017 | 7 | 0.580 |
Why?
|
| Medication Adherence | 5 | 2020 | 387 | 0.580 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 329 | 0.580 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 720 | 0.580 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 606 | 0.580 |
Why?
|
| Inflammation | 15 | 2025 | 1403 | 0.580 |
Why?
|
| Yoga | 1 | 2017 | 12 | 0.570 |
Why?
|
| Biomedical Research | 4 | 2023 | 516 | 0.570 |
Why?
|
| Health Status | 7 | 2022 | 373 | 0.570 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 225 | 0.560 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 2 | 2013 | 6 | 0.540 |
Why?
|
| Patient Discharge | 3 | 2021 | 486 | 0.540 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2015 | 1681 | 0.530 |
Why?
|
| Psychological Techniques | 1 | 2016 | 6 | 0.530 |
Why?
|
| Risk Factors | 22 | 2024 | 10009 | 0.520 |
Why?
|
| Young Adult | 18 | 2024 | 8832 | 0.520 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 621 | 0.510 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 797 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 713 | 0.500 |
Why?
|
| Stroke | 2 | 2023 | 955 | 0.500 |
Why?
|
| Respiratory Therapy | 4 | 2019 | 21 | 0.500 |
Why?
|
| Stress, Psychological | 2 | 2018 | 555 | 0.490 |
Why?
|
| Depressive Disorder | 3 | 2017 | 449 | 0.490 |
Why?
|
| Adolescent | 23 | 2024 | 19075 | 0.490 |
Why?
|
| Aminopyridines | 2 | 2013 | 53 | 0.490 |
Why?
|
| Benzamides | 2 | 2013 | 106 | 0.480 |
Why?
|
| Patient Participation | 1 | 2017 | 220 | 0.470 |
Why?
|
| Precision Medicine | 5 | 2024 | 306 | 0.470 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 138 | 0.460 |
Why?
|
| Physicians, Primary Care | 2 | 2012 | 94 | 0.460 |
Why?
|
| Allergens | 4 | 2025 | 248 | 0.460 |
Why?
|
| Ipratropium | 3 | 2011 | 7 | 0.450 |
Why?
|
| Needs Assessment | 3 | 2021 | 173 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2021 | 1071 | 0.450 |
Why?
|
| Budesonide | 3 | 2020 | 19 | 0.440 |
Why?
|
| Acute Disease | 10 | 2015 | 1093 | 0.430 |
Why?
|
| Patient Safety | 2 | 2017 | 394 | 0.430 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16043 | 0.420 |
Why?
|
| Patient Preference | 3 | 2020 | 115 | 0.420 |
Why?
|
| Health Care Costs | 3 | 2014 | 364 | 0.410 |
Why?
|
| Fluticasone | 5 | 2023 | 15 | 0.410 |
Why?
|
| Cohort Studies | 12 | 2024 | 4699 | 0.400 |
Why?
|
| Time Factors | 12 | 2020 | 6218 | 0.400 |
Why?
|
| Longitudinal Studies | 9 | 2024 | 1305 | 0.400 |
Why?
|
| Recovery of Function | 3 | 2019 | 437 | 0.400 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 6371 | 0.400 |
Why?
|
| Delayed-Action Preparations | 5 | 2020 | 110 | 0.400 |
Why?
|
| Decision Making | 1 | 2017 | 651 | 0.390 |
Why?
|
| Influenza Vaccines | 3 | 2006 | 473 | 0.390 |
Why?
|
| Respiration, Artificial | 5 | 2022 | 458 | 0.390 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2011 | 2 | 0.390 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 2110 | 0.380 |
Why?
|
| Prospective Studies | 14 | 2024 | 6027 | 0.380 |
Why?
|
| Clinical Competence | 3 | 2012 | 973 | 0.380 |
Why?
|
| Managed Care Programs | 1 | 2011 | 61 | 0.370 |
Why?
|
| Bronchoconstriction | 2 | 2008 | 17 | 0.370 |
Why?
|
| Interleukin-13 | 5 | 2024 | 96 | 0.370 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 163 | 0.360 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2011 | 91 | 0.360 |
Why?
|
| Symptom Assessment | 2 | 2021 | 98 | 0.350 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 449 | 0.350 |
Why?
|
| Health Resources | 1 | 2011 | 115 | 0.350 |
Why?
|
| Smokers | 2 | 2022 | 39 | 0.350 |
Why?
|
| Pregnancy Complications | 2 | 2005 | 507 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 6 | 2018 | 1258 | 0.340 |
Why?
|
| Lung Diseases, Obstructive | 3 | 2007 | 34 | 0.340 |
Why?
|
| Evidence-Based Medicine | 5 | 2015 | 622 | 0.340 |
Why?
|
| Peak Expiratory Flow Rate | 5 | 2019 | 17 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2010 | 233 | 0.330 |
Why?
|
| Pulmonary Medicine | 3 | 2015 | 24 | 0.330 |
Why?
|
| Vitamin D | 1 | 2011 | 159 | 0.320 |
Why?
|
| Prognosis | 7 | 2019 | 4512 | 0.320 |
Why?
|
| Patient Selection | 4 | 2019 | 683 | 0.310 |
Why?
|
| Breath Tests | 3 | 2020 | 179 | 0.310 |
Why?
|
| Clinical Trials as Topic | 7 | 2023 | 1080 | 0.310 |
Why?
|
| Fungi | 2 | 2021 | 69 | 0.310 |
Why?
|
| Salmeterol Xinafoate | 7 | 2013 | 13 | 0.300 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 265 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 3076 | 0.300 |
Why?
|
| Respiratory System | 2 | 2022 | 95 | 0.290 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2011 | 84 | 0.290 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 197 | 0.290 |
Why?
|
| Phytotherapy | 1 | 2007 | 50 | 0.290 |
Why?
|
| Leukocyte Count | 4 | 2024 | 246 | 0.290 |
Why?
|
| Antiviral Agents | 2 | 2023 | 743 | 0.290 |
Why?
|
| Signal Transduction | 7 | 2019 | 4493 | 0.280 |
Why?
|
| Vasodilator Agents | 2 | 1998 | 203 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2025 | 2055 | 0.280 |
Why?
|
| Risk Assessment | 7 | 2020 | 3313 | 0.280 |
Why?
|
| Animals | 16 | 2025 | 33796 | 0.270 |
Why?
|
| Injections, Subcutaneous | 4 | 2024 | 126 | 0.270 |
Why?
|
| Isoproterenol | 1 | 2006 | 105 | 0.270 |
Why?
|
| Activities of Daily Living | 3 | 2023 | 404 | 0.270 |
Why?
|
| Anti-Anxiety Agents | 3 | 2019 | 72 | 0.260 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 182 | 0.260 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2010 | 657 | 0.260 |
Why?
|
| Age Factors | 9 | 2024 | 2799 | 0.250 |
Why?
|
| Bronchi | 2 | 2019 | 98 | 0.250 |
Why?
|
| Patient Readmission | 2 | 2020 | 368 | 0.250 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2005 | 22 | 0.240 |
Why?
|
| Sex Factors | 4 | 2024 | 1260 | 0.240 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 423 | 0.240 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 3367 | 0.240 |
Why?
|
| Nutrition Surveys | 3 | 2024 | 289 | 0.230 |
Why?
|
| Respiratory Mucosa | 1 | 2025 | 91 | 0.230 |
Why?
|
| Interleukin-4 | 3 | 2022 | 138 | 0.230 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 288 | 0.230 |
Why?
|
| Maintenance Chemotherapy | 2 | 2020 | 20 | 0.230 |
Why?
|
| Expectorants | 2 | 2017 | 7 | 0.220 |
Why?
|
| Airway Remodeling | 2 | 2021 | 21 | 0.220 |
Why?
|
| General Practitioners | 1 | 2023 | 17 | 0.220 |
Why?
|
| Emphysema | 2 | 2016 | 66 | 0.220 |
Why?
|
| Child | 11 | 2024 | 24221 | 0.220 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 5038 | 0.220 |
Why?
|
| Nasal Polyps | 1 | 2023 | 24 | 0.210 |
Why?
|
| Polysomnography | 1 | 2024 | 140 | 0.210 |
Why?
|
| Doxycycline | 1 | 2023 | 115 | 0.210 |
Why?
|
| Rhinitis | 1 | 2023 | 38 | 0.210 |
Why?
|
| Dry Powder Inhalers | 2 | 2020 | 4 | 0.210 |
Why?
|
| Biological Factors | 1 | 2022 | 28 | 0.200 |
Why?
|
| Vaccination | 2 | 2006 | 944 | 0.200 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2022 | 6 | 0.200 |
Why?
|
| Drug Overdose | 1 | 2022 | 63 | 0.200 |
Why?
|
| Exhalation | 2 | 2020 | 10 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 419 | 0.200 |
Why?
|
| Sinusitis | 1 | 2023 | 117 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 173 | 0.190 |
Why?
|
| Respiratory Insufficiency | 2 | 2015 | 231 | 0.190 |
Why?
|
| Magnesium Sulfate | 1 | 2022 | 50 | 0.190 |
Why?
|
| Cytokines | 4 | 2023 | 1284 | 0.190 |
Why?
|
| Antimetabolites | 1 | 2021 | 33 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 60 | 0.190 |
Why?
|
| Machine Learning | 1 | 2024 | 220 | 0.190 |
Why?
|
| Lung Diseases | 3 | 2025 | 378 | 0.190 |
Why?
|
| Drug Monitoring | 2 | 2020 | 154 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 2014 | 118 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 228 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2023 | 193 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2021 | 372 | 0.180 |
Why?
|
| Respiratory System Agents | 1 | 2020 | 2 | 0.180 |
Why?
|
| Societies, Medical | 4 | 2023 | 676 | 0.180 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 17 | 0.180 |
Why?
|
| Protective Factors | 1 | 2021 | 84 | 0.180 |
Why?
|
| Aftercare | 1 | 2021 | 143 | 0.180 |
Why?
|
| Biostatistics | 1 | 2020 | 10 | 0.180 |
Why?
|
| Immune System | 2 | 2011 | 87 | 0.180 |
Why?
|
| Time | 1 | 2020 | 94 | 0.180 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2020 | 8 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2008 | 196 | 0.180 |
Why?
|
| Health Policy | 2 | 2020 | 213 | 0.170 |
Why?
|
| Home Care Services | 1 | 2020 | 67 | 0.170 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2020 | 17 | 0.170 |
Why?
|
| House Calls | 1 | 2020 | 37 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2017 | 1242 | 0.170 |
Why?
|
| Blood Volume | 1 | 2020 | 80 | 0.170 |
Why?
|
| Cyclopropanes | 2 | 2013 | 67 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2025 | 639 | 0.170 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 10 | 0.170 |
Why?
|
| Patient Admission | 2 | 2018 | 184 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2020 | 65 | 0.170 |
Why?
|
| Equipment Design | 5 | 2020 | 604 | 0.170 |
Why?
|
| Sickness Impact Profile | 2 | 2011 | 36 | 0.160 |
Why?
|
| Receptors, Interleukin-5 | 1 | 2019 | 4 | 0.160 |
Why?
|
| Rewarming | 1 | 1999 | 12 | 0.160 |
Why?
|
| Critical Care | 3 | 2015 | 648 | 0.160 |
Why?
|
| Receptors, Leukotriene | 1 | 2019 | 6 | 0.160 |
Why?
|
| Leukotrienes | 1 | 2019 | 7 | 0.160 |
Why?
|
| Pharmaceutical Solutions | 1 | 2018 | 8 | 0.160 |
Why?
|
| Theophylline | 1 | 2018 | 29 | 0.160 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 65 | 0.160 |
Why?
|
| Hypothermia | 1 | 1999 | 55 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 141 | 0.150 |
Why?
|
| Respiration | 1 | 2019 | 122 | 0.150 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 1072 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 207 | 0.150 |
Why?
|
| Ozone | 1 | 1998 | 18 | 0.150 |
Why?
|
| Pulmonologists | 1 | 2018 | 4 | 0.150 |
Why?
|
| Health Services | 2 | 2016 | 71 | 0.150 |
Why?
|
| Respiratory Mechanics | 2 | 2017 | 75 | 0.150 |
Why?
|
| Receptors, Interleukin-13 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Cysteine | 1 | 2019 | 134 | 0.150 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 1876 | 0.150 |
Why?
|
| Exercise Test | 2 | 2016 | 249 | 0.150 |
Why?
|
| Logistic Models | 4 | 2022 | 1796 | 0.150 |
Why?
|
| Community Health Services | 1 | 2018 | 88 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 172 | 0.150 |
Why?
|
| Calcitonin | 1 | 2017 | 31 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2019 | 141 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 135 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2020 | 470 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2021 | 548 | 0.140 |
Why?
|
| Lung Injury | 1 | 2019 | 122 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 68 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2018 | 179 | 0.140 |
Why?
|
| Drug Tolerance | 1 | 2017 | 40 | 0.140 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 183 | 0.140 |
Why?
|
| Air Pollutants | 1 | 1998 | 101 | 0.140 |
Why?
|
| Diaphragm | 1 | 2017 | 99 | 0.140 |
Why?
|
| Resuscitation | 1 | 1999 | 244 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 146 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 455 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2020 | 528 | 0.130 |
Why?
|
| Mental Health | 1 | 2019 | 345 | 0.130 |
Why?
|
| Quinolones | 2 | 2013 | 54 | 0.130 |
Why?
|
| Beclomethasone | 1 | 1995 | 1 | 0.130 |
Why?
|
| Pregnenediones | 1 | 1995 | 1 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2016 | 116 | 0.130 |
Why?
|
| Sleep Medicine Specialty | 1 | 2015 | 6 | 0.130 |
Why?
|
| Indans | 2 | 2013 | 53 | 0.130 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 459 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 195 | 0.130 |
Why?
|
| Social Support | 1 | 2018 | 345 | 0.130 |
Why?
|
| Health Education | 1 | 2017 | 225 | 0.130 |
Why?
|
| Self Care | 1 | 2017 | 213 | 0.130 |
Why?
|
| Marijuana Smoking | 1 | 2015 | 32 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 233 | 0.120 |
Why?
|
| Obesity | 2 | 2017 | 2230 | 0.120 |
Why?
|
| Prostaglandins | 2 | 2022 | 47 | 0.120 |
Why?
|
| Cannabis | 1 | 2015 | 41 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2022 | 381 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 434 | 0.120 |
Why?
|
| Aspergillus fumigatus | 1 | 2015 | 41 | 0.120 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2015 | 19 | 0.120 |
Why?
|
| Fatigue | 2 | 2016 | 216 | 0.120 |
Why?
|
| Area Under Curve | 3 | 2014 | 314 | 0.120 |
Why?
|
| Health Behavior | 1 | 2018 | 381 | 0.120 |
Why?
|
| Psychometrics | 3 | 2015 | 656 | 0.120 |
Why?
|
| Drug Resistance | 2 | 2013 | 255 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2017 | 356 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2017 | 293 | 0.120 |
Why?
|
| Bronchitis | 2 | 2011 | 34 | 0.120 |
Why?
|
| Age Distribution | 2 | 2017 | 406 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 475 | 0.120 |
Why?
|
| Age of Onset | 2 | 2016 | 581 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2826 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 93 | 0.110 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2014 | 36 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 138 | 0.110 |
Why?
|
| Personnel, Hospital | 1 | 1994 | 34 | 0.110 |
Why?
|
| Ambroxol | 2 | 2017 | 4 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1099 | 0.110 |
Why?
|
| Caregivers | 2 | 2023 | 571 | 0.110 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 1993 | 4 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2013 | 71 | 0.110 |
Why?
|
| Mucociliary Clearance | 1 | 2013 | 4 | 0.110 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 1993 | 21 | 0.110 |
Why?
|
| Bone Density | 1 | 1995 | 313 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 586 | 0.110 |
Why?
|
| Hospital Costs | 2 | 2011 | 177 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2012 | 279 | 0.100 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 101 | 0.100 |
Why?
|
| Survival Rate | 1 | 2017 | 1999 | 0.100 |
Why?
|
| Educational Measurement | 2 | 2012 | 324 | 0.100 |
Why?
|
| Noninvasive Ventilation | 1 | 2013 | 30 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3233 | 0.100 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2012 | 6 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2015 | 286 | 0.100 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2011 | 13 | 0.100 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 22 | 0.100 |
Why?
|
| Length of Stay | 3 | 2013 | 1288 | 0.100 |
Why?
|
| Histone Deacetylase 2 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 254 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 641 | 0.100 |
Why?
|
| Bronchography | 1 | 2011 | 4 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2012 | 957 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 715 | 0.100 |
Why?
|
| Pyruvic Acid | 1 | 2011 | 36 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 390 | 0.100 |
Why?
|
| HIV Infections | 2 | 2022 | 1852 | 0.100 |
Why?
|
| Oxygen | 1 | 2015 | 550 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2013 | 666 | 0.090 |
Why?
|
| Psychology | 1 | 2011 | 56 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2017 | 626 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 1305 | 0.090 |
Why?
|
| Albuterol, Ipratropium Drug Combination | 1 | 2011 | 2 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 1412 | 0.090 |
Why?
|
| Rest | 1 | 2011 | 59 | 0.090 |
Why?
|
| Italy | 2 | 2022 | 111 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2011 | 75 | 0.090 |
Why?
|
| Palliative Care | 1 | 2015 | 428 | 0.090 |
Why?
|
| Budesonide, Formoterol Fumarate Drug Combination | 1 | 2010 | 2 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2013 | 434 | 0.090 |
Why?
|
| Developing Countries | 1 | 2012 | 267 | 0.090 |
Why?
|
| Frail Elderly | 1 | 2011 | 94 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2023 | 1162 | 0.090 |
Why?
|
| Osteomyelitis | 1 | 1993 | 204 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1733 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 310 | 0.090 |
Why?
|
| Propensity Score | 1 | 2011 | 211 | 0.090 |
Why?
|
| Observation | 1 | 2010 | 42 | 0.090 |
Why?
|
| Isomerism | 1 | 2010 | 31 | 0.090 |
Why?
|
| Bronchoscopy | 1 | 2011 | 153 | 0.090 |
Why?
|
| Propranolol | 1 | 2010 | 128 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 280 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2010 | 85 | 0.080 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 861 | 0.080 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2010 | 52 | 0.080 |
Why?
|
| Proteins | 2 | 2014 | 1037 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1230 | 0.080 |
Why?
|
| Powders | 2 | 2008 | 25 | 0.080 |
Why?
|
| Vibration | 1 | 2008 | 31 | 0.080 |
Why?
|
| Immunity | 1 | 2009 | 180 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2021 | 402 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2011 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2011 | 233 | 0.080 |
Why?
|
| Internet | 1 | 2011 | 378 | 0.080 |
Why?
|
| Justicia | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tylophora | 1 | 2007 | 3 | 0.070 |
Why?
|
| Picrorhiza | 1 | 2007 | 3 | 0.070 |
Why?
|
| Minority Groups | 2 | 2022 | 253 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 93 | 0.070 |
Why?
|
| Endopeptidases | 1 | 2008 | 113 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 36 | 0.070 |
Why?
|
| Curcumin | 1 | 2007 | 41 | 0.070 |
Why?
|
| Half-Life | 1 | 2007 | 156 | 0.070 |
Why?
|
| Heart Rate | 2 | 2008 | 586 | 0.070 |
Why?
|
| Pulmonary Alveoli | 1 | 2008 | 134 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 241 | 0.070 |
Why?
|
| Remission Induction | 2 | 2024 | 300 | 0.070 |
Why?
|
| Medicare | 2 | 2020 | 424 | 0.070 |
Why?
|
| Aerosols | 2 | 2017 | 65 | 0.070 |
Why?
|
| Incidence | 4 | 2017 | 3039 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2011 | 769 | 0.060 |
Why?
|
| Endocytosis | 1 | 2006 | 124 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2007 | 269 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 4285 | 0.060 |
Why?
|
| Single-Blind Method | 3 | 2008 | 235 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2006 | 334 | 0.060 |
Why?
|
| Recurrence | 3 | 2015 | 1418 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 303 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 1473 | 0.060 |
Why?
|
| Nucleotides, Cyclic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Infant | 1 | 2020 | 12356 | 0.060 |
Why?
|
| Ontario | 2 | 1997 | 64 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2007 | 381 | 0.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2005 | 18 | 0.060 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2005 | 11 | 0.060 |
Why?
|
| Vaccines, Inactivated | 1 | 2006 | 144 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2006 | 212 | 0.060 |
Why?
|
| Carboxylic Acids | 1 | 2005 | 24 | 0.060 |
Why?
|
| Focus Groups | 2 | 2020 | 199 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 62 | 0.060 |
Why?
|
| Equipment and Supplies | 1 | 2005 | 23 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 257 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2025 | 67 | 0.060 |
Why?
|
| Methacholine Chloride | 2 | 2009 | 21 | 0.060 |
Why?
|
| Amides | 1 | 2005 | 83 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2008 | 1325 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2020 | 365 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2757 | 0.060 |
Why?
|
| Unsupervised Machine Learning | 1 | 2024 | 12 | 0.060 |
Why?
|
| Nitriles | 1 | 2005 | 145 | 0.060 |
Why?
|
| Canada | 2 | 2015 | 294 | 0.060 |
Why?
|
| Receptors, Muscarinic | 1 | 2024 | 14 | 0.060 |
Why?
|
| Cough | 2 | 2016 | 86 | 0.060 |
Why?
|
| Mass Screening | 1 | 2010 | 785 | 0.060 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2004 | 122 | 0.060 |
Why?
|
| Chemokine CCL26 | 1 | 2023 | 1 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 537 | 0.060 |
Why?
|
| Linear Models | 3 | 2016 | 669 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 180 | 0.060 |
Why?
|
| Safety | 1 | 2004 | 218 | 0.060 |
Why?
|
| Societies | 1 | 2023 | 26 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2004 | 96 | 0.050 |
Why?
|
| Placebos | 1 | 2004 | 238 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2003 | 74 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 256 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 148 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2024 | 399 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1389 | 0.050 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 8 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 1997 | 378 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2002 | 35 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2023 | 148 | 0.050 |
Why?
|
| Research Design | 2 | 2020 | 676 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 62 | 0.050 |
Why?
|
| Health Surveys | 2 | 2018 | 241 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 121 | 0.050 |
Why?
|
| Vasculitis | 1 | 2002 | 49 | 0.050 |
Why?
|
| Intensive Care Units | 2 | 2016 | 483 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 270 | 0.050 |
Why?
|
| Pregnancy | 2 | 2005 | 7137 | 0.050 |
Why?
|
| Glomerulonephritis | 1 | 2002 | 73 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2004 | 435 | 0.050 |
Why?
|
| Biological Availability | 1 | 2002 | 128 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 37 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 43 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 607 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1782 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 164 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 180 | 0.050 |
Why?
|
| Antigens, Fungal | 1 | 2021 | 34 | 0.050 |
Why?
|
| Sleep | 1 | 2024 | 344 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 201 | 0.050 |
Why?
|
| Neutrophils | 1 | 2023 | 373 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2017 | 1172 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2020 | 24 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 1548 | 0.050 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2002 | 147 | 0.040 |
Why?
|
| Diet | 1 | 2007 | 1128 | 0.040 |
Why?
|
| Receptors, Interleukin-4, Type II | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 20 | 0.040 |
Why?
|
| Gene Expression | 2 | 2020 | 1565 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 85 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 83 | 0.040 |
Why?
|
| Enterotoxins | 1 | 2020 | 82 | 0.040 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 2019 | 2 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 76 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2019 | 13 | 0.040 |
Why?
|
| Tremor | 2 | 2013 | 129 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 131 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 304 | 0.040 |
Why?
|
| Bronchial Provocation Tests | 1 | 1998 | 14 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1998 | 50 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2018 | 34 | 0.040 |
Why?
|
| Alprostadil | 1 | 1998 | 27 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 96 | 0.040 |
Why?
|
| Skin Tests | 1 | 1998 | 73 | 0.040 |
Why?
|
| Epoprostenol | 1 | 1998 | 67 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 96 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 500 | 0.040 |
Why?
|
| Functional Residual Capacity | 1 | 2017 | 14 | 0.040 |
Why?
|
| Total Lung Capacity | 1 | 2017 | 12 | 0.040 |
Why?
|
| Iowa | 1 | 2017 | 13 | 0.040 |
Why?
|
| Metabolome | 1 | 2020 | 292 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2004 | 1479 | 0.040 |
Why?
|
| Respiratory Tract Infections | 2 | 2013 | 263 | 0.040 |
Why?
|
| Carbocysteine | 1 | 2017 | 1 | 0.040 |
Why?
|
| Thioglycolates | 1 | 2017 | 6 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 1998 | 307 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1998 | 353 | 0.040 |
Why?
|
| Network Meta-Analysis | 1 | 2017 | 29 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2020 | 630 | 0.040 |
Why?
|
| Metformin | 1 | 2019 | 147 | 0.040 |
Why?
|
| Thiophenes | 1 | 2017 | 60 | 0.030 |
Why?
|
| Immunosenescence | 1 | 2016 | 4 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 2017 | 73 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 279 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1010 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2016 | 46 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 65 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 382 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 7 | 0.030 |
Why?
|
| Chemokines, CC | 1 | 2016 | 28 | 0.030 |
Why?
|
| Interleukins | 1 | 2017 | 118 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 742 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2016 | 41 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 674 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1995 | 41 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1995 | 76 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 249 | 0.030 |
Why?
|
| Osteocalcin | 1 | 1995 | 40 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 426 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 966 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2016 | 152 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 282 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1995 | 215 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 169 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2014 | 105 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 1200 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 84 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 151 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2014 | 318 | 0.030 |
Why?
|
| Bone and Bones | 1 | 1995 | 262 | 0.030 |
Why?
|
| Ethiopia | 1 | 1993 | 21 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 1994 | 92 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 696 | 0.030 |
Why?
|
| Nasopharyngitis | 1 | 2013 | 5 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 406 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1993 | 151 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 1994 | 60 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2013 | 81 | 0.030 |
Why?
|
| Ribs | 1 | 1993 | 45 | 0.030 |
Why?
|
| Spasm | 1 | 2013 | 48 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 291 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 171 | 0.030 |
Why?
|
| Emigration and Immigration | 1 | 1993 | 81 | 0.030 |
Why?
|
| Tachycardia | 1 | 2013 | 68 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 1994 | 182 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 184 | 0.030 |
Why?
|
| Internal Medicine | 1 | 1994 | 147 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 1442 | 0.030 |
Why?
|
| Hospitals | 1 | 1995 | 392 | 0.020 |
Why?
|
| Headache | 1 | 2013 | 108 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 142 | 0.020 |
Why?
|
| Potassium | 1 | 2013 | 279 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 803 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 219 | 0.020 |
Why?
|
| Education | 1 | 2012 | 105 | 0.020 |
Why?
|
| Radioactive Tracers | 1 | 2011 | 20 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 48 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 295 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 143 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2011 | 105 | 0.020 |
Why?
|
| Radiography | 1 | 1993 | 822 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2011 | 271 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2010 | 5 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2533 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 261 | 0.020 |
Why?
|
| Physical Examination | 1 | 2011 | 163 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2010 | 40 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 284 | 0.020 |
Why?
|
| Lymphoma | 1 | 1993 | 324 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 533 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 767 | 0.020 |
Why?
|
| Alprenolol | 1 | 2009 | 10 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2009 | 11 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 449 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1638 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3560 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 1119 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 861 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 43 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 103 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 393 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 558 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2587 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3651 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 665 | 0.020 |
Why?
|
| Arrestins | 1 | 2006 | 28 | 0.020 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2006 | 26 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1002 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 458 | 0.020 |
Why?
|
| Epinephrine | 1 | 2006 | 175 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 274 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1691 | 0.020 |
Why?
|
| Protein Transport | 1 | 2006 | 369 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 332 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 810 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 459 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 899 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2012 | 13888 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1994 | 1158 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 1610 | 0.010 |
Why?
|
| Causality | 1 | 2002 | 83 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 137 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 139 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4355 | 0.010 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 1996 | 3 | 0.010 |
Why?
|
| Electronics, Medical | 1 | 1996 | 9 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 361 | 0.010 |
Why?
|
| Bias | 1 | 1996 | 124 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1996 | 120 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 17540 | 0.010 |
Why?
|
| Algorithms | 1 | 1998 | 1596 | 0.010 |
Why?
|